Results 21 to 30 of about 51,507 (268)

Treatment of endometriosis by aromatase inhibitors: efficacy and side effects [PDF]

, 2010
The recent demonstration that aromatase is expressed at higher levels in endometriosis implants than in normal endometrium has led to pilot studies using inhibitor aromatasis in patients with endometriosis.
A.C. Racine, C. Lefebvre-Lacoeuille, E. Hoppé, E. Legrand, L. Catala, L. Sentilhes, P. Descamps   +6 more
core   +4 more sources

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an italian survey. [PDF]

, 2015
The aim of this study was the identification of subgroups of patients at higher risk of nonadherence to adjuvant hormone therapy for breast cancer. Using recursive partitioning and amalgamation (RECPAM) analysis, the highest risk was observed in the ...
Cianchetti E, Fabbri MA, Fanizza C, Fattoruso SI, Gambale E, Gamucci T, Gori S, Grassadonia A, Laudadio L, Longo F, Mauri M, Mazzilli L, Moscetti L, Natoli C., Nuzzo A, Romero M, SEMINARA, Patrizia, Tinari N, Vaccaro A, Vici P   +19 more
core   +1 more source

Possibilities of immunogistochemical investigation in respons prognosis to treatment and modification of treatment activities at luminal breast cancer (literature review).

Medičnì Perspektivi, 2017
This article is concerned with both standard (estrogen and progesterone receptors, Her2/neu and Ki67) immu­nohistochemical investigation in hormonal therapy tactics decision for luminal breast cancer and additional in­vestigation of such hormonal ...
I. M. Bondarenko, V. F. Zavizion, M. V. Artemenko, M. I. Hojouj, L. O. Maltseva, І. V. Bilenkyi, V. А. Hurtovyi, V. V. Lohvynenko, A. V. Prokhach   +8 more
doaj   +1 more source

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer [PDF]

, 2015
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common.
A Mackay, AK Dunbier, AK Dunbier, Alan Mackay, Alexey Larionov, Anita K Dunbier, Aradhana Rani, Ash Nerurkar, B Weigelt, BP Coe, C Curtis, C Kent, D Generali, DG Albertson, DS Tan, Elena López-Knowles, F Kreisel, Helen Anderson, HW Cheung, IE Smith, IE Smith, J Hicks, J Michael Dixon, Jorge S Reis-Filho, JS Foster, K Lundgren, L Osterberg, LA Martin, LA Martin, LA Martin, Lesley-Ann Martin, LG Leon, Lorna Renshaw, M Dowsett, M Mello-Grand, M Scaltriti, Mitch Dowsett, MJ Ellis, MT Weigel, N Turner, P Darbre, P Lal, Paul M Wilkerson, Peter Osin, PM Wilkerson, PM Wilkerson, PT Simpson, R Beroukhim, R Duprez, R Katz-Brull, R Natrajan, R Natrajan, R Natrajan, Ricardo Ribas, T Miyake, T Troiani, TK Lam, William R Miller, WR Miller, WR Miller, WR Miller, WR Miller, X Huo, Y Zhao, Z Ghazoui, Zara Ghazoui   +65 more
core   +3 more sources

Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis

Reproductive Biology and Endocrinology, 2011
Background The present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and structural similarity. Human aromatase is well known as an important pharmacological target in anti-breast cancer therapy, but recent research ...
Mustata Gabriela, Muftuoglu Yagmur
doaj   +1 more source

Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]

, 2012
Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core   +2 more sources

Managing menopausal symptoms and associated clinical issues in breast cancer survivors [PDF]

, 2017
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +5 more
core   +1 more source

New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity

Molecules, 2023
A novel series of 1,2,3-triazole/1,2,4-triazole hybrids 5a, 5b, and 6a–i was designed and synthesized as antiproliferative agents targeting aromatase enzymes.
Mohamed T-E Maghraby, Tahani Mazyad Almutairi, Stefan Bräse, Ola I. A. Salem, Bahaa G. M. Youssif, Mahmoud M. Sheha   +5 more
doaj   +1 more source

Inhibition of rainbow trout (Oncorhynchus mykiss) P450 aromatase activities in brain and ovarian microsomes by various environmental substances [PDF]

, 2006
International audienceAromatase, a key steroidogenic enzyme that catalyses the conversion of androgens to estrogens, represent a target for endocrine disrupting chemicals.
Brion, François, Hinfray, Nathalie, Porcher, Jean-Marc   +2 more
core   +3 more sources

Locally Advanced Breast Cancer Patient’s Recurrence Rates Comparison Received Steroidal and Nonsteroidal Aromatase Inhibitor Based on Luminal

Biomolecular and Health Science Journal
Introduction: Aromatase inhibitors are hormonal therapies used in menopausal breast cancer with positive progesterone receptors and/or estrogen receptors.
Desak Gede Agung Suprabawati, Bernadeta Hernik Setiyandari, Dwi Hari Susilo, Bara Kharisma, Rizki Amalia   +4 more
doaj   +1 more source